|
시장보고서
상품코드
1983259
타크로리무스 시장 : 제품 유형별, 용도별, 최종사용자별, 지역별Tacrolimus Market, By Product Type, By Application, By End User, By Geography |
||||||
타크로리무스 시장은 2026년에 127억 달러로 추정되며, 2033년까지 166억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 7.2%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 127억 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 7.20% | 2033년 시장 규모 예측: | 166억 달러 |
타크로리무스는 칼시뉴린 억제제이며 강력한 면역억제제로서 주로 장기 이식 후 세포성 거부반응을 예방하기 위해 사용됩니다. 또한 중증 아토피성 피부염, 골수 이식 후 난치성 중증 포도막염, 피부질환인 백반증 치료에 외용제로도 사용됩니다. 타크로리무스는 캡슐제, 경구 현탁액용 과립제(액체에 혼합하여 사용), 서방형(장기지속형) 캡슐제, 경구용 서방형 정제로 시판되고 있습니다. 타크로리무스의 속방성 제제는 다른 면역억제제와 함께 동종 간, 신장, 심장, 폐 이식을 받은 성인 및 소아 환자의 장기 거부반응 예방에 대한 승인을 받았습니다. 타크로리무스의 서방형 제제는 다른 면역억제제와 병용하여 신장 이식을 받은 성인 및 소아 환자의 장기 거부반응을 예방하기 위해 승인되었으며, 속방형 제제에서 전환한 환자에게도 사용되기도 합니다.
시장 역학
시장 내 주요 기업들의 신제품 출시 증가는 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2020년 6월 노바티스의 제네릭 의약품 및 바이오시밀러 분야의 세계 리더인 Sandoz는 1일 1회 복용 타크로리무스 제네릭 캡슐을 독일, 영국, 네덜란드, 핀란드, 스웨덴, 에스토니아, 라트비아, 이탈리아, 스페인, 슬로베니아에서 'Dailiport'라는 이름으로 출시하였습니다. 슬로바키아에서는 'Dailiport'로, 이탈리아와 스페인에서는 'Conferoport'로 발매한다고 발표했습니다.
또한, 시장의 주요 기업들은 타크로리무스 제품 유통과 같은 비유기적 성장 전략에 집중하고 있으며, 이는 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2022년 1월, 호주에 본사를 둔 전문 제약회사 메이네 제약그룹(Mayne Pharma Group Limited)은 미국에서 타크로리무스 연고 0.1%를 판매하기 시작했다고 발표했습니다. 타크로리무스 연고는 아토피 피부염 치료에 사용되는 '프로토픽'의 제네릭 의약품입니다.
본 조사의 주요 특징.
- 이 보고서는 세계 타크로리무스 시장에 대한 상세한 분석을 제공하며, 2021년을 기준 연도로 하여 예측 기간(2022-2030년)의 시장 규모와 CAGR%를 제시합니다.
- 이 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트도 제공합니다.
- 이 보고서는 다음과 같은 매개 변수를 기반으로 세계 타크로리무스 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가1 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 타크로리무스 시장 분석에 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 타크로리무스 시장 : 제품 유형별, 2026-2033년
제5장 세계의 타크로리무스 시장 : 용도별, 2026-2033년
제6장 세계의 타크로리무스 시장 : 최종사용자별, 2026-2033년
제7장 세계의 타크로리무스 시장 : 지역별, 2026-2033년
제8장 경쟁 구도
제9장 애널리스트의 추천
제10장 섹션
KSM 26.04.20Tacrolimus Market is estimated to be valued at USD 12.7 Bn in 2026 and is expected to reach USD 16.6 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 12.7 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.20% | 2033 Value Projection: | USD 16.6 Bn |
Tacrolimus is a calcineurin inhibitor and potent immunosuppressive drug that is primarily used to prevent cellular rejection following organ transplantation. It is also used topically to treat severe atopic dermatitis, severe refractory uveitis following bone marrow transplants, and the skin disorder vitiligo. Tacrolimus is available in capsule, granules for oral suspension (to be combined with liquid), extended-release (long acting) capsule, and extended-release tablet for oral administration. Tacrolimus immediate-release formulations, in combination with other immunosuppressants, are approved for the prevention of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants. Tacrolimus extended-release formulations are approved for the prevention of organ rejection in adult and pediatric patients having kidney transplants when combined with other immunosuppressants, and may be used in patients who have been converted from immediate-release formulations.
Market Dynamics
The increasing product launch by the key players in the market is expected to drive the market growth over the forecast period. For instance, in June 2020, Sandoz, a Novartis division and a global leader in generic pharmaceuticals and biosimilars, announced the launch of once-daily generic tacrolimus capsules known as Dailiport in Germany, the U.K., The Netherlands, Finland, Sweden, Estonia, Latvia, and Slovakia, and as Conferoport in Italy and Spain.
Moreover, key companies in the market are focusing on inorganic growth strategies such as distribution of tacrolimus products, which is expected to drive the market growth over the forecast period. For instance, in January 2022, Mayne Pharma Group Limited, an Australia-based specialty pharmaceutical company announced that it had begun distribution of tacrolimus ointment, 0.1% in the U.S. Tacrolimus ointment is a generic version of PROTOPIC, indicated for the treatment of Atopic dermatitis.
Key features of the study
- This report provides an in-depth analysis of the global tacrolimus market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global tacrolimus market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG, Mylan N.V., Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Pfizer Inc., Abbott, Senju Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Ltd., Lupin Limited, and Vibcare Pharma Pvt. Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global tacrolimus market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tacrolimus market
Market Segmentation
- By Product Type
- Tacrolimus Capsules and Tablets
- Tacrolimus Ointment
- Tacrolimus Injection
- Tacrolimus Granules
- By Application
- Immunosuppression
- Dermatitis
- Others
- By End User
- Organ Transplant Centers
- Hospitals
- Clinics
- Others
- By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis AG
- Mylan N.V.
- Astellas Pharma Inc.
- Reddy's Laboratories Ltd.
- Pfizer Inc.
- Abbott
- Senju Pharmaceutical Co. Ltd.
- Glenmark Pharmaceuticals Ltd.
- Lupin Limited
- Vibcare Pharma Pvt. Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Application
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- PEST Analysis
- PORTER's Five Forces Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend
4. Global Tacrolimus Market, By Product Type, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Tacrolimus Capsules and Tablets
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Tacrolimus Ointment
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Tacrolimus Injection
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Tacrolimus Granules
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
5. Global Tacrolimus Market, By Application, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Immunosuppression
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Dermatitis
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global Tacrolimus Market, By End User, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Organ Transplant Centers
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospitals
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Clinics
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
7. Global Tacrolimus Market, By Region, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By End User, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By End User, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By End User, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By End User, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By End User, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By End User, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3x3 Matrix)
- Company Profiles
- Novartis AG
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Mylan N.V.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Astellas Pharma Inc.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Pfizer Inc.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Abbott
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Senju Pharmaceutical Co. Ltd.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Glenmark Pharmaceuticals Ltd.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Lupin Limited
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Vibcare Pharma Pvt. Ltd.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Novartis AG
9. Analyst Recommendation
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. Section
- References
- Research Methodology
- About Us and Sales Contact
